Form 4: Hims & Hers CFO Trades Shares Under 10b5-1 Plan

Hims & Hers Health, Inc. Chief Financial Officer, Oluyemi Okupe, executed a stock option exercise and subsequent sale of shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported transactions on April 6, 2026.
• These transactions involved the exercise of stock options and the sale of Class A Common Stock.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on May 21, 2025.
• 3,975 shares were acquired through option exercise at a price of $5.01 per share.
• Subsequently, 3,975 shares were sold at an average weighted price of $19.977 per share, with individual sales ranging from $19.95 to $20.02.
• Following these transactions, Okupe beneficially owns 318,789 shares directly and 7,853 shares indirectly through a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a significant number of shares being sold by a key executive, the pre-planned nature of the transaction under a Rule 10b5-1 plan mitigates concerns about opportunistic selling.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-impactful trading activity.
• The CFO exercised options at $5.01 and sold shares at a significantly higher average price of $19.977, realizing a profit.

Negatives

• The sale of a significant number of shares by a key executive could be interpreted negatively by the market, although it was pre-planned.
• The filing details the sale of shares, which reduces the CFO's direct holdings.

Risks

• While the transactions were made under a 10b5-1 plan, any significant selling by insiders can create negative sentiment.
• The vesting schedule for the remaining options indicates a phased release of shares over time, subject to continued service.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person.
• Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $19.95-$20.02).
• The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider transactions, especially those under Rule 10b5-1 plans, are common for executives managing their personal portfolios and diversifying holdings. The significant spread between the option exercise price and the sale price suggests a profitable outcome for the executive, which is typical when options are exercised well after their grant date and the stock price has appreciated.

Stakeholder Impact

• Shareholders: The sale of shares by the CFO, even under a 10b5-1 plan, might lead to short-term market perception concerns, though the pre-planned nature aims to reduce impact.
• Employees: The vesting schedule for options indicates continued incentive for employees to remain with the company.
• Management: Demonstrates adherence to established trading plans for personal financial management.

Next Steps

• The remaining 75% of the stock options will vest in a series of thirty-six (36) successive equal monthly installments starting from the twelve (12) month anniversary of the Vesting Commencement Date, subject to continued service.
• The reporting person may provide further details on share sales at specific prices upon request from regulatory bodies, the issuer, or security holders.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Rule 10b5-1, Hims & Hers Health, HIMS, Oluyemi Okupe, CFO, Share Sale, Beneficial Ownership